Azacitidine for the treatment of patients with acute myeloid leukemia with 20%–30% blasts and multilineage dysplasia-Reference-Cited by-同舟云学术

Azacitidine for the treatment of patients with acute myeloid leukemia with 20%–30% blasts and multilineage dysplasia

Published:2011-03 Issue:S3 Volume:28 Page:1-9
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Therapy

Author:

Font Patricia

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12325-011-0002-8.pdf

Reference33 articles.

1. Silverman LR. Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS) Oncologist. 2001;6(suppl. 5):8–14.

2. Leone G, Teofili L, Voso MT, Lübbert M. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica. 2002;87:1324–1341.

3. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088.

4. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292–2302.

5. EPAR-Product Information. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000978/WC500050239.pdf ). Accessed February 1, 2011.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Determination of 5-azacitidine in human plasma by LC–MS/MS: application to pharmacokinetics pilot study in MDS/AML patients;Cancer Chemotherapy and Pharmacology;2023-03

2. Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy;Leukemia Research;2020-06

3. Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies;Oncotarget;2016-06-14

4. Progress in Acute Myeloid Leukemia;Clinical Lymphoma Myeloma and Leukemia;2015-03

5. Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure;Leukemia Research;2014-04